biote Corp. Form 8-K Summary
Business Context and Reporting Period
biote Corp. filed a Form 8-K regarding a secondary offering of its Class A common stock. The underwriting agreement was entered into on June 5, 2023, and the offering closed on June 7, 2023. The shares were sold by a selling stockholder; the filing does not indicate that biote Corp. issued shares or received offering proceeds.
Transaction and Key Metrics
- Base offering: 5,217,392 shares of Class A common stock.
- Offering price: $5.35 per share, before underwriting discounts and commissions.
- Underwriter: Roth Capital Partners, LLC.
- Additional shares: The underwriter had a 30-day option for up to 782,608 additional shares and partially exercised it for 576,108 shares.
- Total shares sold, including the partial option exercise: 5,793,500.
- Implied gross transaction value based on the stated price: approximately $31.0 million, before underwriting discounts, commissions, and expenses. These proceeds were payable to the selling stockholder.
- The filing provides no new revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.
Material Changes Versus Prior Comparable Period
The filing does not present comparative financial results. The material event is the secondary sale of shares, which may increase the public float but does not, based on the filing, provide financing to biote Corp. or change its reported operating results.
Guidance, Outlook, Risks, and Unusual Items
- No guidance or financial outlook is provided.
- The underwriting agreement includes customary representations, warranties, closing conditions, indemnification obligations, and termination provisions.
- The shares were registered under an effective Form S-1 registration statement, as amended.
- The filing does not describe unusual contingencies beyond the customary contractual obligations associated with the offering.
Important Facts for Investors to Verify
- Confirm the final number of shares sold and the extent of the underwriter’s option exercise.
- Verify that the transaction was a selling-stockholder offering and that biote Corp. did not receive the gross or net proceeds.
- Review the underwriting agreement filed as Exhibit 1.1 for indemnification, termination, and other contractual provisions.
- Assess the effect of the additional shares on public float, ownership concentration, and potential selling pressure.
- Review subsequent filings for updated ownership information and any additional sales by the selling stockholder.